BRPI0915417A2 - derivados de 3-(3-pirimidin-2-il-benzil)-[1,2,4]triazolo [4,3-b]piridazina como inibidores da met quinase - Google Patents

derivados de 3-(3-pirimidin-2-il-benzil)-[1,2,4]triazolo [4,3-b]piridazina como inibidores da met quinase

Info

Publication number
BRPI0915417A2
BRPI0915417A2 BRPI0915417A BRPI0915417A BRPI0915417A2 BR PI0915417 A2 BRPI0915417 A2 BR PI0915417A2 BR PI0915417 A BRPI0915417 A BR PI0915417A BR PI0915417 A BRPI0915417 A BR PI0915417A BR PI0915417 A2 BRPI0915417 A2 BR PI0915417A2
Authority
BR
Brazil
Prior art keywords
metinase
triazolo
pyrimidin
inhibitors
benzyl
Prior art date
Application number
BRPI0915417A
Other languages
English (en)
Inventor
Andree Blaukat
Dieter Dorsch
Frank Stieber
Oliver Schadt
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BRPI0915417A2 publication Critical patent/BRPI0915417A2/pt
Publication of BRPI0915417B1 publication Critical patent/BRPI0915417B1/pt
Publication of BRPI0915417B8 publication Critical patent/BRPI0915417B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0915417A 2008-06-18 2009-05-25 derivados de 3-(3-pirimidin-2-il-benzil)-[1,2,4]triazolo [4,3-b]piridazina BRPI0915417B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102008028905A DE102008028905A1 (de) 2008-06-18 2008-06-18 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
DE102008028905.1 2008-06-18
PCT/EP2009/003675 WO2009152920A1 (de) 2008-06-18 2009-05-25 3-(3-pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazin-derivative als met-kinase inhibitoren

Publications (3)

Publication Number Publication Date
BRPI0915417A2 true BRPI0915417A2 (pt) 2015-11-03
BRPI0915417B1 BRPI0915417B1 (pt) 2020-02-11
BRPI0915417B8 BRPI0915417B8 (pt) 2021-05-25

Family

ID=40973097

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915417A BRPI0915417B8 (pt) 2008-06-18 2009-05-25 derivados de 3-(3-pirimidin-2-il-benzil)-[1,2,4]triazolo [4,3-b]piridazina

Country Status (19)

Country Link
US (1) US8497266B2 (pt)
EP (1) EP2285811B1 (pt)
JP (1) JP5662311B2 (pt)
KR (1) KR101661777B1 (pt)
CN (1) CN102066378B (pt)
AR (1) AR072860A1 (pt)
AU (1) AU2009259764B2 (pt)
BR (1) BRPI0915417B8 (pt)
CA (1) CA2728194C (pt)
DE (1) DE102008028905A1 (pt)
DK (1) DK2285811T3 (pt)
EA (1) EA019534B1 (pt)
ES (1) ES2400117T3 (pt)
IL (1) IL210063A (pt)
MX (1) MX2010013649A (pt)
PL (1) PL2285811T3 (pt)
PT (1) PT2285811E (pt)
WO (1) WO2009152920A1 (pt)
ZA (1) ZA201100437B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102007038957A1 (de) * 2007-08-17 2009-02-19 Merck Patent Gmbh 6-Thioxo-pyridazinderivate
DE102007061963A1 (de) * 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
DE102008019907A1 (de) * 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
DE102008037790A1 (de) * 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
DE102008063667A1 (de) * 2008-12-18 2010-07-01 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
SI2361250T1 (sl) 2008-12-22 2013-12-31 Merck Patent Gmbh Nove polimorfne oblike 6-(1-metil-1h-pirazol-4-il)-2-(3-(5-(2-morfolin-4-il-etoksi)-pirimidin- 2-il)-benzil)-2h-piridazin-3-on dihidrogenfosfata in postopki za proizvodnjo le-tega
DE102008062825A1 (de) 2008-12-23 2010-06-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
EP3010922B1 (en) * 2013-06-19 2017-03-15 Galapagos NV Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201321745D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
US11180480B2 (en) 2017-10-17 2021-11-23 Sensorion Synthesis of 4-aminopyrimidine compounds

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE19604388A1 (de) 1996-02-07 1997-08-14 Merck Patent Gmbh Arylalkyl-diazinone
DE69720965T2 (de) 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
JPH10259176A (ja) 1997-03-17 1998-09-29 Japan Tobacco Inc 血管新生阻害作用を有する新規アミド誘導体及びその用途
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
TWI241295B (en) * 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
AUPQ462299A0 (en) 1999-12-13 2000-01-13 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
US6242461B1 (en) * 2000-01-25 2001-06-05 Pfizer Inc. Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
ES2572030T3 (es) 2001-08-10 2017-07-19 Shionogi & Co., Ltd. Agente antiviral
US20040259863A1 (en) * 2001-10-31 2004-12-23 Hans-Michael Eggenweiler Type 4 phosphodiesterase inhibitors and uses thereof
ZA200504898B (en) 2002-12-20 2006-11-29 Pharmacia Corp Acyclic pyrazole compounds
JP2007516180A (ja) 2003-07-02 2007-06-21 スゲン，インコーポレイティド ｃ−Ｍｅｔ阻害薬としてのアリールメチルトリアゾロおよびイミダゾピラジン類
US7959919B2 (en) * 2003-11-19 2011-06-14 Novelmed Therapeutics, Inc. Method of inhibiting factor B-mediated complement activation
TW200612918A (en) 2004-07-29 2006-05-01 Threshold Pharmaceuticals Inc Lonidamine analogs
US20070043057A1 (en) * 2005-02-09 2007-02-22 Threshold Pharmaceuticals, Inc. Lonidamine analogs
US20070015771A1 (en) * 2004-07-29 2007-01-18 Threshold Pharmaceuticals, Inc. Lonidamine analogs
EP1912977A4 (en) 2005-08-03 2009-10-21 Merck Frosst Canada Ltd EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS
WO2007044796A2 (en) 2005-10-11 2007-04-19 Nps Pharmaceuticals, Inc. Pyridazinone compounds as calcilytics
KR20080080584A (ko) * 2005-11-30 2008-09-04 버텍스 파마슈티칼스 인코포레이티드 ｃ-Ｍｅｔ의 억제제 및 이의 용도
DE102005057924A1 (de) 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
HRP20170103T1 (hr) * 2005-12-21 2017-03-24 Janssen Pharmaceutica N.V. Triazolopiridazini kao modulatori tirozin kinaze
WO2007130383A2 (en) 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
CA2651979A1 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Triazolopyridazine derivatives
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
KR101083177B1 (ko) 2006-10-23 2011-11-11 에스지엑스 파마슈티컬스, 인코포레이티드 트리아졸로-피리다진 단백질 키나제 조정제
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
DE102007026341A1 (de) * 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
JP2011500629A (ja) 2007-10-16 2011-01-06 ノバルティス アーゲー 神経ペプチドｙ２受容体のモジュレーターとしての置換ピペラジンおよびピペリジン
JP2011500778A (ja) 2007-10-25 2011-01-06 アストラゼネカ・アクチエボラーグ ピリジン及びピラジン誘導体−０８３
WO2009057827A1 (en) * 2007-10-31 2009-05-07 Nissan Chemical Industries, Ltd. Pyridazinone derivatives and use thereof as p2x7 receptor inhibitors
TW200927115A (en) 2007-11-16 2009-07-01 Boehringer Ingelheim Int Aryl-and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
WO2009080534A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
AR069869A1 (es) 2007-12-21 2010-02-24 Exelixis Inc Derivados de benzofuro[3,2-d]pirimidinas inhibidores de proteinquinasas,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer.
AU2008340421B2 (en) 2007-12-21 2013-12-19 F. Hoffmann-La Roche Ag Heteroaryl derivatives as orexin receptor antagonists
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
CL2008003785A1 (es) 2007-12-21 2009-10-09 Du Pont Compuestos derivados de piridazina; composiciones herbicidas que comprenden a dichos compuestos; y método para controlar el crecimiento de la vegetación indeseada.
CA2709514A1 (en) 2007-12-21 2009-07-02 Astrazeneca Ab Bicyclic derivatives for use in the treatment of androgen receptor associated conditions
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
US7816540B2 (en) 2007-12-21 2010-10-19 Hoffmann-La Roche Inc. Carboxyl- or hydroxyl-substituted benzimidazole derivatives
EP2242483B1 (en) 2007-12-21 2013-02-20 Synthon B.V. Raloxifene composition
EP2072506A1 (de) 2007-12-21 2009-06-24 Bayer CropScience AG Thiazolyloxyphenylamidine oder Thiadiazolyloxyphenylamidine und deren Verwendung als Fungizide
CN101903385B (zh) 2007-12-21 2013-11-06 帕劳制药股份有限公司 作为组胺h4受体拮抗剂的4-氨基嘧啶衍生物
DE102007061963A1 (de) * 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
GB0725059D0 (en) 2007-12-21 2008-01-30 Syngenta Participations Ag Novel pyridazine derivatives
CN101537006B (zh) * 2008-03-18 2012-06-06 中国科学院上海药物研究所 哒嗪酮类化合物在制备抗肿瘤药物中的用途
DE102008019907A1 (de) * 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
WO2009142732A2 (en) * 2008-05-20 2009-11-26 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
EP2323994A1 (en) * 2008-07-25 2011-05-25 Boehringer Ingelheim International GmbH Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
BRPI1013159A2 (pt) * 2009-03-30 2015-09-15 Sumitomo Chemical Co Uso de composto de piridazinona para controle de peste artrópode
AR082590A1 (es) * 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton

Also Published As

Publication number Publication date
AR072860A1 (es) 2010-09-29
PL2285811T3 (pl) 2013-04-30
CA2728194C (en) 2016-11-29
BRPI0915417B1 (pt) 2020-02-11
MX2010013649A (es) 2010-12-21
AU2009259764B2 (en) 2013-09-26
PT2285811E (pt) 2013-03-05
ES2400117T3 (es) 2013-04-05
EP2285811A1 (de) 2011-02-23
EA201100031A1 (ru) 2011-08-30
DK2285811T3 (da) 2013-03-11
ZA201100437B (en) 2011-09-28
JP2011524385A (ja) 2011-09-01
JP5662311B2 (ja) 2015-01-28
US8497266B2 (en) 2013-07-30
CA2728194A1 (en) 2009-12-23
AU2009259764A1 (en) 2009-12-23
KR101661777B1 (ko) 2016-09-30
CN102066378A (zh) 2011-05-18
DE102008028905A1 (de) 2009-12-24
IL210063A (en) 2015-06-30
WO2009152920A1 (de) 2009-12-23
IL210063A0 (en) 2011-02-28
US20110092498A1 (en) 2011-04-21
KR20110031329A (ko) 2011-03-25
EP2285811B1 (de) 2012-12-05
EA019534B1 (ru) 2014-04-30
BRPI0915417B8 (pt) 2021-05-25
CN102066378B (zh) 2014-04-16

Similar Documents

Publication Publication Date Title
BRPI0915417A2 (pt) derivados de 3-(3-pirimidin-2-il-benzil)-[1,2,4]triazolo [4,3-b]piridazina como inibidores da met quinase
BR112012002110A2 (pt) derivados de pirrolo[1,2-b]piridazina como inibidores de janus cinase
BRPI0919948A2 (pt) Pirido[4,3-b]indois contendo porções rígidas
BRPI0722088A2 (pt) derivados de pirrolo[2,3-b]piridina como moduladores de cinase
LTPA2018510I1 (lt) Dioksa-biciklo[3.2.1]oktan-2,3,4-triolio dariniai
BRPI0919292A2 (pt) 3h-imidazo[4,5-b] piridina-6-carboxamidas como agentes anti-inflamatórios
SMT201400123B (it) Imidazo[1,2B]piridazine sostituite come inibitori di trk-chinasi
BRPI1008850A2 (pt) [1,2,4]triazolo[1,5-a]piridinas como inibidores de quinase
BRPI1011515A2 (pt) derivados de pirrolo[2,3-b] piridina para a inibição de raf cinases
EP2341052A4 (en) RING-CONDENSED MORPHOLINE DERIVATIVITY WITH PI3K-INHIBITING EFFECT
BRPI1014459A2 (pt) derivados de 3-(1,2,3-triazol-4-il)pirrolo[2,3-b]-piridina"
EP2608669A4 (en) NEW PYRAZOLO- [1,5-A-] PYRIMIDINE DERIVATIVES AS ANTI-MTOR HEMMER
DOP2011000388A (es) Carboxamidas 5-fenilo-[1,2,4] triazolo [1,5-a] piridina-2-il como inhibidores jak
IL212285A0 (en) Azaindole derivatives
BRPI0913580A2 (pt) pirrolopiridinas como inibidores de quinase
EP2327704A4 (en) RING-CONDENSED AZOL DERIVATIVE WITH PI3K-INHIBITING EFFECT
BRPI0914301A2 (pt) derivados de pirimidin-4-ona substituída
IL211241A0 (en) 7-azaindole derivatives
BRPI0821936A2 (pt) Derivados de 4-(pirrolo[2,3-c]piridina-3-il)pirimidin-2-ilamina
AP2010005521A0 (en) Macrocyclic indole derivatives useful as hepatitisvirus inhibitors.
BR112012002801A2 (pt) derivados de 3-heteroarilmetil-imidazo[1,2-b]piridazin-6-ila como moduladores de tirosina quinase c-met
EP2511276A4 (en) Pyrrolo [2,3-D] pyrimidine derivative
ZA201105257B (en) 3-(3-pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyrimidine derivatives
EP2490693A4 (en) Pyrazolo [3,4-B] PYRIDINE-4-ON-KINASE INHIBITORS
BRPI1012581A2 (pt) derivados de amidas de ácido 6, 7-di-hidro-5h-imidazol[1,2-a]imidazol-3-carboxílico

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/02/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/05/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2776 DE 19-03-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.